A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease (PD) Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control

Trial Profile

A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease (PD) Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Levodopa (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Acorda Therapeutics; Civitas Therapeutics
  • Most Recent Events

    • 18 Jun 2018 According to an Acorda Therapeutics media release, data were previously presented at the American Academy of Neurology Annual Meeting in April 2018.
    • 18 Jun 2018 According to an Acorda Therapeutics media release, data will be presented at the upcoming 2nd Pan American Parkinsons Disease and Movement Disorders Congress 2018.
    • 29 May 2018 According to an Acorda Therapeutics media release, based on the data from this trial, European Medicines Agency has completed formal validation of Marketing Authorization Application for INBRIJA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top